Connection

Contact Us
If you have any questions or feedback please contact us.

Search Results to Wells Alton Messersmith

This is a "connection" page, showing the details of why an item matched the keywords from your search.

Search Results

Messersmith, Wells

One or more keywords matched the following items that are connected to Messersmith, Wells

Item Type	Name
Academic Article	Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients.
Academic Article	A rapid and sensitive method for determination of sorafenib in human plasma using a liquid chromatography/tandem mass spectrometry assay.
Academic Article	Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
Academic Article	[18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy.
Academic Article	Antitumor effects and biomarkers of activity of AZD0530, a Src inhibitor, in pancreatic cancer.
Academic Article	Gene array and fluorescence in situ hybridization biomarkers of activity of saracatinib (AZD0530), a Src inhibitor, in a preclinical model of colorectal cancer.
Academic Article	Phase I safety, pharmacokinetic, and pharmacodynamic study of ENMD-2076, a novel angiogenic and Aurora kinase inhibitor, in patients with advanced solid tumors.
Academic Article	Current status of SRC inhibitors in solid tumor malignancies.
Academic Article	Phase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors.
Academic Article	Phase I study of Rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and Polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer.
Academic Article	Stromal cell-derived factor 1a mediates resistance to mTOR-directed therapy in pancreatic cancer.
Academic Article	The development of regorafenib and its current and potential future role in cancer therapy.
Academic Article	Association of the epithelial-to-mesenchymal transition phenotype with responsiveness to the p21-activated kinase inhibitor, PF-3758309, in colon cancer models.
Academic Article	Novel targets in solid tumors: MEK inhibitors.
Academic Article	New strategies in colorectal cancer: biomarkers of response to epidermal growth factor receptor monoclonal antibodies and potential therapeutic targets in phosphoinositide 3-kinase and mitogen-activated protein kinase pathways.
Academic Article	Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer.
Academic Article	A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors.
Academic Article	Biomarker-driven trial in metastatic pancreas cancer: feasibility in a multicenter study of saracatinib, an oral Src inhibitor, in previously treated pancreatic cancer.
Academic Article	A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer.
Academic Article	Common PIK3CA mutants and a novel 3' UTR mutation are associated with increased sensitivity to saracatinib.
Academic Article	Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.
Academic Article	Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.
Concept	MAP Kinase Signaling System
Concept	MAP Kinase Kinase 2
Concept	Mitogen-Activated Protein Kinases
Concept	Mitogen-Activated Protein Kinase Kinases
Concept	Protein Kinase Inhibitors
Concept	Cyclin-Dependent Kinase Inhibitor p21
Concept	CDC2 Protein Kinase
Concept	src-Family Kinases
Concept	Protein Kinases
Concept	MAP Kinase Kinase Kinases
Concept	Phosphatidylinositol 3-Kinases
Concept	Focal Adhesion Kinase 1
Concept	MAP Kinase Kinase 1
Academic Article	A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins.
Academic Article	Rational combination of a MEK inhibitor, selumetinib, and the Wnt/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancer.
Academic Article	Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies.
Academic Article	Dual pharmacological targeting of the MAP kinase and PI3K/mTOR pathway in preclinical models of colorectal cancer.
Academic Article	Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer.
Academic Article	Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model.
Academic Article	ALDH1B1 Is Crucial for Colon Tumorigenesis by Modulating Wnt/?-Catenin, Notch and PI3K/Akt Signaling Pathways.
Academic Article	Combined inhibition of MEK and Aurora A kinase in KRAS/PIK3CA double-mutant colorectal cancer models.
Academic Article	A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.
Academic Article	Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts.
Academic Article	Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.
Academic Article	Regulation of Head and Neck Squamous Cancer Stem Cells by PI3K and SOX2.
Academic Article	Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer.
Grant	Evaluation of Src Inhibition in Pancreas Cancer
Grant	Evaluation of BAY43-9006/Cetuximab in Colorectal Cancer
Grant	Biomarker-Driven Src Inhibitor Studies in Colorectal Cancer Patients
Grant	Evaluation of Oral EGFR Inhibitors in Colorectal Cancer
Academic Article	Evaluation of the efficacy of dasatinib, a Src/Abl inhibitor, in colorectal cancer cell lines and explant mouse model.
Academic Article	Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancer.
Academic Article	Cabozantinib Exhibits Potent Antitumor Activity in Colorectal Cancer Patient-Derived Tumor Xenograft Models via Autophagy and Signaling Mechanisms.
Academic Article	Phase Ib Results of the Rational Combination of Selumetinib and Cyclosporin A in Advanced Solid Tumors with an Expansion Cohort in Metastatic Colorectal Cancer.
Academic Article	Dual compartmental targeting of cell cycle and angiogenic kinases in colorectal cancer models.
Academic Article	A Phase I Dose-Escalation Study of Linsitinib (OSI-906), a Small-Molecule Dual Insulin-Like Growth Factor-1 Receptor/Insulin Receptor Kinase Inhibitor, in Combination with Irinotecan in Patients with Advanced Cancer.
Academic Article	CDK1 Interacts with Sox2 and Promotes Tumor Initiation in Human Melanoma.
Concept	Aurora Kinase A
Concept	Aurora Kinases
Concept	Class I Phosphatidylinositol 3-Kinases
Concept	Phosphatidylinositol 3-Kinase
Concept	TOR Serine-Threonine Kinases
Academic Article	Comprehensive Genomic Landscapes in Early and Later Onset Colorectal Cancer.
Academic Article	Preclinical and Dose-Finding Phase I Trial Results of Combined Treatment with a TORC1/2 Inhibitor (TAK-228) and Aurora A Kinase Inhibitor (Alisertib) in Solid Tumors.
Academic Article	ATM kinase inhibitor AZD0156 in combination with irinotecan and 5-fluorouracil in preclinical models of colorectal cancer.

Search Criteria

Phosphotransferases